PARP Inhibitors in Prostate and Urothelial Cancers

Frontiers in Oncology

Yousef Zakharia¹  Rohan Garje¹  Raju Kumar Vaddepally² 

[1] Division of Hematology, Oncology, and Blood and Marrow Transplant, Holden Comprehensive Cancer Center, University of Iowa, Iowa City, IA, United States;Yuma Regional Medical Center, Yuma, AZ, United States;

关键词: prosate cancer;    urothelial cancer (UC);    PARP inhibitor;    precision oncology;    DNA damage repair genes;   

DOI  :  10.3389/fonc.2020.00114

来源: DOAJ

【 摘 要 】

Poly(ADP-ribose) polymerase (PARP) inhibitors targeting DNA repair gene mutations have shown significant clinical benefit in patients with ovarian and breast cancers. In metastatic prostate cancers, the prevalence of DNA repair gene mutations is up to 20%, and early phase studies have shown clinical activity of PARP inhibitors. Numerous clinical trials with either PARP monotherapy or in combination with other therapeutic agents are ongoing in prostate cancer. In this comprehensive review, we provide the rationale, efficacy, and safety data of PARP inhibitors in prostate as well as urothelial cancers.

【 授权许可】

Unknown